NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.
Details
Age
Adult
Type of Study
Treatment
Locations
Harmony Campus
Memorial Hospital Central
Memorial Hospital North
University of Colorado Hospital
Principal Investigator
Kian Behbakht, MD, MBA
Study ID
Protocol Number: 18-2281
More information available at ClinicalTrials.gov: NCT03660826
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers